highperformr logo

Athira Pharma's Overview

Total employees42
HeadquartersBothell
Founded2011

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company committed to developing novel small-molecule therapeutics designed to restore neuronal health and slow the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Their scientific approach focuses on positively modulating the HGF/MET neurotrophic system, a key pathway in brain function and repair. Athira's lead product candidate, fosgonimeton (ATH-1017), aims to impact neurodegeneration and improve cognitive function by enhancing this system.

Where is Athira Pharma's Headquarters?

HQ Function

The headquarters serves as the primary center for Athira Pharma's research and development activities, clinical operations management, and corporate administrative functions, guiding the company's strategic initiatives.

Notable Features:

Situated within a modern business park tailored to technology and life science companies, the facility likely includes specialized laboratory spaces and office environments designed to support biopharmaceutical innovation. Specific architectural highlights are not publicly emphasized.

Work Culture:

The work culture at Athira Pharma's headquarters is expected to be highly collaborative, scientifically rigorous, and patient-focused, characteristic of a biopharmaceutical company tackling complex neurological disorders. There's likely a strong emphasis on innovation, teamwork, and ethical research practices.

HQ Significance:

The Bothell headquarters is pivotal for Athira, leveraging the region's rich talent pool in biotechnology and its robust infrastructure for life sciences research. It's the command center for their global clinical trial efforts and R&D pipeline.

Values Reflected in HQ: The headquarters likely embodies Athira's core values of scientific excellence, innovation in pursuit of patient solutions, and a dedicated approach to tackling challenging neurodegenerative diseases.

Location:

Athira Pharma's global presence is primarily defined by its international clinical trial operations. To ensure diverse patient populations and robust data for its drug development programs, the company engages with clinical research sites and investigators in North America, Europe, and potentially other regions. While its corporate and primary research functions are centralized in the U.S., its mission to address neurodegenerative diseases has a worldwide scope through these clinical studies and potential future partnerships.

Street Address:

18706 North Creek Parkway, Suite 104

City:

Bothell

State/Province:

WA

Country:

USA

Athira Pharma's Global Presence

Buying Intent Signals for Athira Pharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Athira Pharma

As of April 2025, Athira Pharma' leadership includes:

Mark Litton, Ph.D. - President and Chief Executive Officer
Kevin P. Church, Ph.D. - Chief Scientific Officer
Glenna Mileson - Chief Financial Officer
Javier San Martin, M.D. - Chief Medical Officer
Julie Rathbun - Chief Business Officer

Investors of Athira Pharma

Athira Pharma has been backed by several prominent investors over the years, including:

Perceptive Advisors LLC
RTW Investments, LP
The Vanguard Group, Inc.
BlackRock Inc.
Bain Capital Life Sciences
Franklin Resources, Inc.

Executive New Hires/Exits in the Last 12 Months

Hire3
Exits1

Over the past 12-18 months, Athira Pharma has made significant updates to its executive team, including appointing a new Chief Financial Officer in mid-2023, and a new Chief Business Officer and Chief Scientific Officer in late 2023 and early 2024, respectively. These changes aim to strengthen leadership for its ongoing clinical development and strategic growth.

Departures

Rachel Lenea Hopper, Rachel Lenea Hopper departed from her role as Chief Financial Officer.

New Appointments:

Glenna Mileson, Glenna Mileson was appointed as Chief Financial Officer.
Julie Rathbun, Julie Rathbun was appointed as Chief Business Officer.
Kevin P. Church, Ph.D., Kevin P. Church, Ph.D., was appointed as Chief Scientific Officer.

Technology (Tech Stack) used by Athira Pharma

Discover the tools Athira Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Athira Pharma Email Formats and Examples

Athira Pharma likely uses standard corporate email address formats. The most common pattern observed for companies of similar size and industry is the first initial followed by the last name.

flast@athira.com (e.g., jdoe@athira.com)

Format

example@athira.com

Example

85%

Success rate

News and media

GlobeNewswireMay 16, 2024

Athira Pharma Announces First Patient Enrolled in Phase 2/3 LIFT-AD Open Label Extension Study of Fosgonimeton in Alzheimer’s Disease

Athira Pharma announced the enrollment of the first patient in its LIFT-AD Open Label Extension (OLE) study. This study is designed to evaluate the long-term safety and tolerability of fosgonimeton in patients with mild-to-moderate Alzheimer's disease who previously completed the LIFT-AD Phase 2/3 trial....more

GlobeNewswireMay 9, 2024

Athira Pharma Reports First Quarter 2024 Financial Results and Provides Pipeline Update

Athira Pharma reported its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical development pipeline. Key highlights included progress in the LIFT-AD study for Alzheimer's disease and the SHAPE-PD study for Parkinson's disease dementia or Lewy body dementia....more

GlobeNewswireFebruary 29, 2024

Athira Pharma Reports Full Year 2023 Financial Results and Provides Pipeline Update

Athira Pharma announced its financial results for the full year ended December 31, 2023, and offered updates on its pipeline, including ongoing clinical trials for fosgonimeton in neurodegenerative diseases. The company highlighted its strategic priorities for advancing its therapeutic candidates....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Athira Pharma, are just a search away.